PDGFRB and gastrointestinal stromal tumor: This agent, which inhibits BCR-ABL, platelet-derived growth factor receptor (PDGFR) and c-KIT tyrosine kinases, has rapidly become established as the gold standard therapy for chronic myeloid leukaemia and gastrointestinal stromal tumours (GIST) (Druker, 2002).